Cover Image

A functional enzymatic assay as potential readout for a clinical trial of a schistosomiasis vaccine

An estimated 200 million people are currently infected with schistosomiasis and an additional 800 million reside in high transmission-risk areas in 78 endemic countries. In this report we describe a functional enzymatic assay based on the core calpain antigen (Sm-p80) of the schistosomiasis vaccine,...

Full description

Saved in:
Bibliographic Details
Main Authors: Kifle, Desalegn W. (Author) , Balkhi, Mumtaz Y. (Author) , Ono, Yasuko (Author) , Davis, Jenn (Author) , Doi, Naoko (Author) , Arya, Aryandra (Author) , Kim, Jiho (Author) , Kalyanasundaram, Aravindan (Author) , Nandy, Sourav (Author) , Rakotozandrindrainy, Njariharinjakamampionona (Author) , Staker, Bart (Author) , Craig, Justin (Author) , Rakotozandrindrainy, Raphaël (Author) , Tadesse, Birkneh T. (Author) , Marks, Florian (Author) , Jackson, Lisa (Author) , Carter, Darrick (Author) , Gray, Sean A. (Author) , Siddiqui, Afzal A. (Author)
Format: Article (Journal)
Language:English
Published: 13 March 2025
In: npj vaccines
Year: 2025, Volume: 10, Pages: 1-5
ISSN:2059-0105
DOI:10.1038/s41541-024-01044-2
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41541-024-01044-2
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41541-024-01044-2
Get full text
Author Notes:Desalegn W. Kifle, Mumtaz Y. Balkhi, Yasuko Ono, Jenn Davis, Naoko Doi, Aryandra Arya, Jiho Kim, Aravindan Kalyanasundaram, Sourav Nandy, Njariharinjakamampionona Rakotozandrindrainy, Bart Staker, Justin Craig, Raphaël Rakotozandrindrainy, Birkneh T. Tadesse, Florian Marks, Lisa Jackson, Darrick Carter, Sean A. Gray & Afzal A. Siddiqui
Description
Summary:An estimated 200 million people are currently infected with schistosomiasis and an additional 800 million reside in high transmission-risk areas in 78 endemic countries. In this report we describe a functional enzymatic assay based on the core calpain antigen (Sm-p80) of the schistosomiasis vaccine, SchistoShield®. A 44 kDa soluble variant of the core Sm-p80 antigen (B7), was assessed for its enzymatic activity using a fluorescent synthetic substrate. Inhibition of the B7 enzymatic activity by Sm-p80-specific antibodies obtained from pre-clinical trials in rodents, non-human primates as well as from participants of the human clinical trials was measured. The B7 enzyme activity followed a Michaelis-Menten-like kinetic behavior. Statistically significant inhibition of the B7 activity was observed by Sm-p80-specific antibodies produced by immunized mice, non-human primates and humans. This quantitative serological assay could be of value in assessing the effectiveness of the SchistoShield® vaccine in human trials in Africa.
Item Description:Gesehen am 20.08.2025
Physical Description:Online Resource
ISSN:2059-0105
DOI:10.1038/s41541-024-01044-2

Similar Items